Opalmon


Combined with:

Mucosta

Indications and Reactions:

Role Indications Reactions
Secondary
Hypertension 15.9%
Product Used For Unknown Indication 14.9%
Rheumatoid Arthritis 10.6%
Lumbar Spinal Stenosis 8.7%
Drug Use For Unknown Indication 7.7%
Gastric Ulcer 5.4%
Sciatica 5.0%
Diabetes Mellitus 4.4%
Large Intestine Carcinoma 3.7%
Spinal Column Stenosis 3.3%
Hyperlipidaemia 2.9%
Cerebral Infarction 2.5%
Arteriosclerosis 2.3%
Osteoporosis 2.1%
Cardiovascular Disorder 1.9%
Osteoarthritis 1.9%
Gastritis 1.7%
Prophylaxis Against Gastrointestinal Ulcer 1.7%
Constipation 1.5%
Pain 1.5%
Eosinophil Count Increased 12.9%
Thrombocytopenia 9.7%
Petechiae 8.1%
Toxic Epidermal Necrolysis 8.1%
Pruritus 6.5%
Respiratory Failure 6.5%
Agranulocytosis 4.8%
Interstitial Lung Disease 4.8%
Upper Respiratory Tract Inflammation 4.8%
Atrioventricular Block Third Degree 3.2%
Drug Eruption 3.2%
Eosinophilia 3.2%
Flatulence 3.2%
Pancytopenia 3.2%
Platelet Count Decreased 3.2%
Pneumonia 3.2%
Renal Failure Chronic 3.2%
Second Primary Malignancy 3.2%
Somnolence 3.2%
Asthenia 1.6%
Concomitant
Hypertension 16.8%
Rheumatoid Arthritis 13.1%
Product Used For Unknown Indication 11.7%
Prophylaxis 7.6%
Osteoporosis 5.0%
Drug Use For Unknown Indication 4.5%
Lumbar Spinal Stenosis 4.2%
Pain 4.0%
Constipation 3.9%
Insomnia 3.9%
Gastritis 3.6%
Back Pain 3.4%
Diabetes Mellitus 3.0%
Spinal Column Stenosis 2.9%
Angina Pectoris 2.6%
Hyperlipidaemia 2.4%
Hyperphosphataemia 2.0%
Depression 2.0%
Arteriosclerosis Obliterans 1.8%
Gastric Ulcer 1.7%
Interstitial Lung Disease 11.6%
Rhabdomyolysis 8.4%
White Blood Cell Count Decreased 7.9%
Pneumonia 7.4%
Somnolence 5.6%
Femur Fracture 5.1%
Vomiting 5.1%
Rash 4.7%
Altered State Of Consciousness 4.2%
Death 4.2%
Lung Neoplasm Malignant 4.2%
Pyrexia 4.2%
Condition Aggravated 3.7%
Loss Of Consciousness 3.7%
Urinary Retention 3.7%
Cerebral Infarction 3.3%
Decreased Appetite 3.3%
Myocardial Infarction 3.3%
Nausea 3.3%
Osteomyelitis 3.3%

Drug Data